Previous 10 | Next 10 |
home / stock / fdmt / fdmt articles
4D Molecular Therapeutics Inc (NASDAQ:FDMT) shares are trading lower by 11.7% to $28.33 Wednesday afternoon after the company announced an upsized ...
Monday, 4D Molecular Therapeutics (NASDAQ:FDMT) released interim data from the Phase 2 PRISM clinical trial evaluating intravitreal 4D-15...
U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling around 200 points on Monday. The Dow traded down 0.53% to 38,4...
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 100 points on Monday. The Dow traded down 1.04% to 38,...
4D Molecular Therapeutics (NASDAQ:FDMT) shares are trading higher after the company released interim data from the Phase 2 PRISM clinical tria...
U.S. stocks traded lower, with the Dow Jones falling over 300 points on Monday. Shares of The Estée Lauder Companies Inc. (NYSE: EL) rose s...
U.S. stocks traded lower this morning, with the Dow Jones index falling around 150 points on Monday. Following the market opening Monday, the Dow t...
Shares of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) rose sharply in today’s pre-market trading. 4DMT presented interim data from randomi...
Initial interim landmark data analysis (N=50 at 24 Weeks) will be presented by Arshad M. Khanani, M.D., M.A., FASRS, Principal Investigator of th...
News, Short Squeeze, Breakout and More Instantly...
4D Molecular Therapeutics Inc. Company Name:
FDMT Stock Symbol:
NASDAQ Market:
4D Molecular Therapeutics Inc. Website:
Robust reduction in anti-VEGF injection treatment burden through Week 24 achieved in 30 patients at planned Phase 3 dose (3E10 vg/eye) with 89% reduction in annualized injection rate; 93% of patients received 0 or 1 injection and 77% were injection-free Improvement in mean best corr...
2024-07-11 10:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
4D-175 comprises the proprietary low-dose intravitreal R100 AAV vector and a codon-optimized transgene encoding a highly functional shortened form of human complement factor H (sCFH) Complement factor H (CFH) variants with reduced function are a well-validated genetic risk factor for ge...